<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154800</url>
  </required_header>
  <id_info>
    <org_study_id>CV017-003</org_study_id>
    <nct_id>NCT04154800</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study to Assess Single and Multiple Doses of BMS-986209 in Healthy Participants</brief_title>
  <official_title>A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986209 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety and tolerability of drug BMS-986209 in healthy volunteers.
      It also looks at the movement of BMS-986209 in the body. This first-in-human study is
      designed in 2 parts. In Part A, healthy participants will take a single, oral dose of
      BMS-986209 or placebo. Food effect will also be assessed in Part A. Part A participants may
      be at the study site for up to 5 days. In Part B, healthy participants will take either a
      once- or twice-daily oral dose of BMS-986209 or placebo for 14 days. Part B participants may
      be at the study site for up to 19 days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Day 81</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 81</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with AEs resulting in Study Discontinuation</measure>
    <time_frame>Day 81</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Vital Sign Abnormalities</measure>
    <time_frame>Day 81</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Day 81</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clinical Laboratory Abnormalities</measure>
    <time_frame>Day 81</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: Fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single ascending dose (SAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Ascending Dose (SAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple Ascending Dose (MAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple Ascending Dose (MAD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986209</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A: Fasting</arm_group_label>
    <arm_group_label>Part A: Fed</arm_group_label>
    <arm_group_label>Part B: Fasting</arm_group_label>
    <arm_group_label>Part B: Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A: Fasting</arm_group_label>
    <arm_group_label>Part A: Fed</arm_group_label>
    <arm_group_label>Part B: Fasting</arm_group_label>
    <arm_group_label>Part B: Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Body mass index (BMI) 18.0 to 32.0 kg/m2, inclusive. (BMI = weight (kg)/height[m])2.

          -  Normal renal function at screening.

          -  Female participants not of child-bearing potential.

          -  Males who are sexually active with women of childbearing potential must agree to
             follow instructions for method(s) of contraception: to use a condom during the
             intervention period and for at least 92 days after the last dose of study
             intervention. Azoospermic males are exempt from contraceptive requirements.

          -  Males with a pregnant or breastfeeing partner must agree to remain abstinent from
             penile vaginal intercourse or use a male condom during each episode of such
             intercourse, during the intervention period and for at least 92 days after the last
             dose of study intervention.

          -  Male participants must refrain from donating sperm during the intervention period and
             for at least 92 days after the last dose of study intervention.

        Exclusion Criteria:

          -  Women who are of childbearing potential.

          -  Women who are breastfeeding.

          -  Any acute or chronic medical illness.

          -  History of dizziness and/or recurrent headaches (i.e. daily headaches lasting for a
             1-week duration in the last month prior to study treatment administration).

          -  History of heart disease or conduction disorders.

          -  Head injury in the last 2 years, intracranial tumor, or aneurysm.

          -  Current or history of rectal bleeding, hematemesis, or hematuria.

          -  Known abdominal aneurysm.

          -  History of gastroesophageal reflux disease, inflammatory bowel disease or any
             gastrointestinal disease that could impact the absorption of study treatment.

          -  History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence
             of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent
             unexplained bruising or thrombus formation, or a history of spontaneous bleeding, such
             as epistaxis.

          -  Personal or family history of hemophilia, Rosenthal syndrome, FXIa deficiency, or
             other coagulopathies.

          -  History of systemic lupus erythematosus or any other autoimmune diseases.

          -  Any major surgery within 4 weeks of study treatment administration or planned within 2
             weeks after completion of the study.

          -  Donation of blood to a blood bank or in a clinical study (except a screening visit or
             follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for
             plasma only).

          -  Current or any history of blood transfusion.

          -  Use of tobacco- or nicotine-containing products (including, but not limited to,
             cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine
             lozenges, or nicotine gum) within 6 months prior to study treatment administration).

          -  Current or history of drug or alcohol abuse.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information</last_name>
    <phone>please email</phone>
    <email>ClinicalTrials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

